Palisade Bio vs Yarrow Bioscience
PALI and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PALI and YARW compare
Palisade Bio is the larger company, worth 4.6 times as much as Yarrow Bioscience ($176M against $37.9M).
Yarrow Bioscience keeps more of each dollar of sales as profit, with a net margin of −4646% compared with −6388% at Palisade Bio.
Yarrow Bioscience pays a dividend yielding 142%; Palisade Bio does not pay one.
Yarrow Bioscience scores higher on the StockData Score (11 against 7 for Palisade Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PALI | YARW |
|---|---|---|
| Size and price | ||
| Market cap | $176M | $37.9M |
| Share price | $1.01 | $14.21 |
| Change, 1 year | −52.8% | −24.1% |
| Change, 5 years | −99.9% | −98.5% |
| Beta (5Y) | 1.15 | 2.07 |
| Employees | 100K | 10 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/S | 352× | 66.6× (better) |
| P/B | 1.4× (better) | 1.7× |
| FCF yield | – | −87.3% |
| Fair value | – | $7.04 |
| Margin of safety | – | −102% |
| Growth | ||
| Revenue growth (TTM) | – | 13.8% |
| Revenue growth, 5Y average | – | −51.4% |
| Profitability | ||
| Operating margin | −7070% | −5219% (better) |
| Net margin | −6388% | −4646% (better) |
| FCF margin | – | −5811% |
| Return on equity | −51.4% (better) | −86.9% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −4418.6× | – |
| Current ratio | 24.26 (better) | 15.26 |
| Altman Z-score | 19.21 (better) | −33.58 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | – | 142% |
| Buyback yield | −74.7% | – |
| Shareholder yield | −74.7% | 142% (better) |
| Ownership | ||
| Held by institutions | 99.5% | 11.6% |
| Held by insiders | 4.7% | 82.1% |
| Insider net buying, 12 months | −$124K | – |
| Short interest, % of float | 17.6% | 29.7% |
Go deeper
- PALI stock overview
- PALI income statement
- PALI valuation and score
- YARW stock overview
- YARW income statement
- YARW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.